Discover 920 paid clinical trials in Portland, Oregon. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 920
Prospective Observational Study of Naturopathic Approaches to IBS
for
Irritable Bowel Syndrome (IBS)
Location: Portland OR
Sponsor: National University of Natural Medicine
Sex: All
Age: 18+
Code: NCT06721624
Recruiting
Herbal Evaluation Of Artemisia Annua For Small Intestinal Bacterial Overgrowth
for
Small Intestinal Bacterial Overgrowth Syndrome (SIBO)
Location: Portland OR
Sponsor: National University of Natural Medicine
Sex: All
Age: 18+
Code: NCT06721884
Phase1, Phase2, Recruiting
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
for
Anatomic Stage II Breast Cancer AJCC v8,
Location: Fruitland ID, Post Falls ID, Coeur d'Alene ID,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06058377
Phase3, Recruiting
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
for
Fallopian Tube Endometrioid Adenocarcinoma,
Location: Portland OR, Vancouver WA, Clackamas OR, Tualatin OR,
Sponsor: NRG Oncology
Sex: All
Age: 18+
Code: NCT06580314
Phase3, Recruiting
Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis
for
Plaque Psoriasis
Location: Portland OR, Warrenton OR, Mill Creek WA, Surrey,
Sponsor: Oruka Therapeutics, Inc.
Sex: All
Age: 18 - 70+
Code: NCT07474792
Phase2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
Location: Portland OR, Sacramento CA, Santa Monica CA,
Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Sex: All
Age: 18+
Code: NCT06251310
Phase1, Recruiting
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy